Agretti P, Niccolai F, Rago T, De Marco G, Molinaro A, Scutari M, Di Cosmo C, Di Coscio G, Vitale M, Maccheroni M, Vitti P, Tonacchera M
Department of Clinical and Experimental Medicine, Section of Endocrinology, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
J Endocrinol Invest. 2014 Oct;37(10):1009-14. doi: 10.1007/s40618-014-0166-6. Epub 2014 Sep 7.
Fine-needle aspiration (FNA) with cytologic evaluation is the most reliable tool for malignancy prediction in thyroid nodules, but cytologic diagnosis remains indeterminate for 12-18 % of nodules. BRAF V600E mutation has been reported to show a high specificity for malignant thyroid nodules and the use of this marker to refine indeterminate FNA cytology results may be a useful diagnostic adjunctive tool in the pre-operative evaluation of thyroid nodules. The aim of this study was to estimate the prevalence of BRAF exon 15 mutation (V600E) and its clinical value as a diagnostic tool in a series of thyroid nodules with indeterminate cytology from an area of borderline iodine deficiency.
One hundred and fifty-three thyroid samples obtained by FNA of thyroid nodules from 151 patients were subjected to the analysis of BRAF V600E mutation by direct sequencing. In the study 54 nodules with indeterminate cytology, 56 benign and 43 malignant thyroid nodules were included.
V600E BRAF gene mutation was demonstrated in 19/43 malignant nodules, in 0/56 benign nodules and in only 1/54 indeterminate nodules that, after histology, turned out to be at a papillary thyroid carcinoma.
The application of BRAF exon 15 analysis showed limitations when applied to discriminate thyroid nodules with indeterminate cytology if wild-type BRAF is found, and there is no role for avoiding diagnostic thyroid surgery.
细针穿刺抽吸(FNA)及细胞学评估是预测甲状腺结节恶性程度最可靠的工具,但仍有12% - 18%的结节细胞学诊断为不确定。据报道,BRAF V600E突变对甲状腺恶性结节具有较高的特异性,在术前评估甲状腺结节时,使用该标志物来完善不确定的FNA细胞学结果可能是一种有用的诊断辅助工具。本研究的目的是评估BRAF外显子15突变(V600E)在一系列来自碘缺乏边缘地区、细胞学结果不确定的甲状腺结节中的发生率及其作为诊断工具的临床价值。
对151例患者甲状腺结节FNA获取的153份甲状腺样本进行BRAF V600E突变的直接测序分析。研究纳入了54例细胞学结果不确定的结节、56例良性甲状腺结节和43例恶性甲状腺结节。
在43例恶性结节中有19例检测到V600E BRAF基因突变,56例良性结节中未检测到,54例细胞学结果不确定的结节中仅1例在组织学检查后被证实为甲状腺乳头状癌。
当应用BRAF外显子15分析来鉴别细胞学结果不确定的甲状腺结节时,如果发现BRAF为野生型,则该方法存在局限性,且在避免诊断性甲状腺手术方面无作用。